Semaglutide Predictors DUK Poster 2024

Predictors of response to injectable once-weekly Semaglutide: Insights from the Association of British Clinical Diabetologists nationwide audit 

Authors:

Thomas SJ Crabtree< Karen Adamson, Alex Bickerton, Alison Evans, Suzanne Phillips, Alison Gallagher, Niels Larsen, Dennis Barnes, Ketan Dhatariya, Benjamin CT Field, Iskandar Idris, Robert EJ Ryder on behalf of all ABCD Semaglutide audit contributor

Discipline

Diabetes
Resource taxonomy
Audit Posters
Clinical taxonomy
Obesity Treatments for diabetes Type 2 diabetes mellitus
Listing status
Current

ABCD Corporate Pharma Sponsors

Gold

  • AstraZeneca UK
  • Boehringer Ingelheim and Lilly Alliance
  • Eli Lilly and Company

Silver

  • A Menarini Farmaceutica Internazionale SRL
  • Sanofi

ABCD Corporate Pump & Device Sponsors

Gold

  • Abbott
  • Dexcom
  • Ypsomed Ltd

Silver

  • A. Menarini Diagnostics
  • Advanced Therapeutics (UK) Ltd
  • Air Liquide Healthcare Ltd
  • Insulet International
  • Medtronic Limited

Bronze

  • Roche Diabetes Care

Contact

Address for correspondence: 
ABCD (Diabetes Care) Ltd, 483 Green Lanes, London, N13 4BS

Telephone: 01675 477602
Email: info@abcd.care

Follow Us

ABCD (Diabetes Care) is a company limited by shares in England and Wales under company number 7270377, whose registered address is Fifteen Rosehill, Montgomery Way, Rosehill Estate, Carlisle CA1 2RW Diabetes Care Trust (ABCD) is a registered charity number 1139057, a company limited by guarantee in England and Wales under company number 74248361, whose registered address is Fifteen Rosehill, Montgomery Way, Rosehill Estate, Carlisle CA1 2RW. ABCD (Diabetes Care) Ltd is a wholly owned subsidiary of the Diabetes Care Trust (ABCD) Ltd